[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"atrophic-scar\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:atrophic-scar":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100636744","exososmes-in-atrophic-scars-management-100636744",false,"NCT07569666","Exososmes in Atrophic Scars Management","Evaluation of Intralesional Exosomes Versus Intralesional Saline in The Treatment of Atrophic Scars: A Randomized Controlled Trial","Inclusion Criteria:\n\nAge \\>18 years\n\n* Either gender\n* Scars of any duration\n* Multiple scars at one side or both sides of the face.\n* Patients are willing to sign written informed consent statements before beginning treatment.\n\nExclusion Criteria:\n\n* Pregnant females.\n* Patients with one scar.\n* Hypersensitivity to any of the used treatments.\n* Patient with infection at the site of the scar.\n* Patients with unrealistic expectations.\n* Patient refusing to sign on the consent.","ALL","18 Years",{"count":19,"type":20},12,"ESTIMATED","INTERVENTIONAL",[23],"NA","Lay Summary (Simple Explanation)\n\nAtrophic scars are depressed scars that form when the skin does not heal properly, commonly seen after acne or injuries. These scars can affect appearance and confidence, and current treatments may not always give satisfactory results.\n\nThis study aims to evaluate a new treatment using exosomes, which are tiny particles naturally released by cells that help in skin repair and regeneration. Researchers will compare the effect of injecting exosomes directly into scars versus injecting a simple saltwater solution (saline), which serves as a control.\n\nParticipants will be randomly assigned to receive either exosome injections or saline injections. Neither the patient nor the evaluator may know which treatment is given, to ensure fair comparison.\n\nThe goal is to determine whether exosomes can safely and effectively improve the appearance and texture of atrophic scars.",[26],"Atrophic Scar","RECRUITING","2026-05-01",{"date":30,"type":31},"2026-05-06","ACTUAL",{"date":33,"type":31},"2025-06-15",{"date":35,"type":20},"2027-02",{"name":37,"class":38},"Zagazig University","OTHER_GOV",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":39},"100629422","phase-1-safety-and-efficacy-of-autologous-adipose-derived-mesenchymal-stem-cells-therapy-in-adults-with-atrophic-scars-100629422","NCT07474467","Safety and Efficacy of Autologous Adipose-derived Mesenchymal Stem Cells Therapy in Adults With Atrophic Scars","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Split-Face, Phase 1\u002F2 Study to Evaluate the Safety and Efficacy of a Single Administration of TRTP-101 in Adults With Atrophic Scars","Inclusion Criteria:\n\n* Male or Female aged greater than 19 years\n* Acne scars graded ≥ 3 on the 5-point ASRS\n\n\\[Phase 1\\]\n\n* Four or more atrophic scars in the joints, genitals, perineum, and face except for the lips, eyes and nose\n\n\\[Phase 2\\]\n\n* Atrophic scar lesions approximately 2 cm in diameter located on the cheeks or temple on both sides of the face\n* A response of \"dissatisfied\" or worse on the Subject Acne Scar Self-Assessment Scale\n\nExclusion Criteria:\n\n* History of cell therapy\n* Treatment of Dermal resurfacing, Chemical\u002FMechanical Peel and Skin Photorejuvenation\n* Treatment of Hyaluronic acid\u002Fcollagen skin filler, non-permanent soft tissue filler and fat grafting\n* Positive for virus infection\n* Use of Anticoagulant therapy or NSAIDs\n* Thrombocytopenia or other coagulation disorder\n* History of keloid scars\n* Infectious disease or other dermatitis in the area of the atrophic scar\n* Use of Immunosuppressant, immunomodulating drug, anticancer drug or radiation therapy\n* Use of systemic steroid medication\n* History of hypersensitivity or severe allergic reactions (e.g., anaphylaxis, Guillain-Barre syndrome, etc.)\n* Use of retinoid medications",true,"19 Years",{"count":50,"type":20},31,[52,53],"PHASE1","PHASE2","The purpose of this clinical trial was to evaluate the safety and efficacy of a single administration of TRTP-101 in adults with atrophic scars.",[26],"NOT_YET_RECRUITING","2026-03-11",{"date":59,"type":31},"2026-03-16",{"date":61,"type":20},"2026-08-01",{"date":63,"type":20},"2029-08-01",{"name":65,"class":66},"CellinCells","INDUSTRY",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":47,"sex":16,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":4},"100539034","the-efficacy-of-combination-therapy-in-atrophic-scars-100539034","NCT06298591","The Efficacy of Combination Therapy in Atrophic Scars","The Efficacy of Subcision in Combination With PRP Injection and Fractional Co2 Laser in Treatment of Atrophic Scar: Clinical and Ultrasonic Study","Inclusion Criteria:\n\n\\- Patients aged from 12 to 60 years with\n\n* post inflammatory atrophic scar.\n* post traumatic atrophic scar.\n* post operative atrophic scar\n\nExclusion Criteria:\n\n* post acne scar.\n* active skin infection.","12 Years","70 Years",{"count":77,"type":20},45,[23],"There are more than 100 million patients who develop scar formation caused by various factors, such as post-inflammatory acne and trauma (1). They often have physical, aesthetic, psychological, and social barriers. Scar tissue is naturally a stage of wound healing. Abnormal wound healing produces a spectrum of scar tissue types such as atrophic, hypertrophic, and keloid scars (2).\n\nAtrophic scars are dermal depressions, which are commonly caused by the destruction of collagen following inflammatory process. This permanent disfiguring sequelae correlates with the duration of pathology, severity of lesion, and delay in therapy (3).\n\nTreatment of atrophic acne scars remains a therapeutic challenge, yet there is no standard option as the most effective treatment (4). A range of possible options has been investigated including surgical techniques (subcision, non-ablative laser treatment, resurfacing techniques (ablative laser treatment, dermabrasion), and injection or dermal fillers or fat, and a combination of two or more modalities (5).\n\nUltrasound is a unique non-invasive and non-radiating medical imaging tool in the investigation of dermatological diseases by providing detailed anatomic and physiologic data of skin lesions and deeper soft tissue changes. Lesion size in three dimensions-lengths, width, and depth, morphology, the detailed anatomic information provided by sonography is useful to assessment of effect of different types of treatment modality to improve atrophic scar and avoid invasive assessment tools as punch biopsy for histopathological examination (6)",[26],"2024-03-06",{"date":83,"type":31},"2024-03-07",{"date":85,"type":20},"2024-03-15",{"date":87,"type":20},"2027-03-15",{"name":89,"class":90},"Assiut University","OTHER"]